GORE® EXCLUDER®
AAA Endoprosthesis

OUTCOMES THAT OUTPERFORM

Across 15 years of U.S. Medicare claims data,[1,2] long-term reintervention and rupture rates were lowest in patients treated with the GORE® EXCLUDER® Device.[3]

Reintervention Rate



No at risk									
Early AFX	942	770	669	551	472	244	128	51	20
Endurant	6606	4609	3256	2242	1455	903	498	241	108
Zenith	3281	2427	1865	1419	1014	648	363	197	110
Late AFX	1350	947	584	259	<11				
Excluder	8310	5576	3799	2602	1643	995	544	292	163

Late AAA Rupture Rate



No at risk									
Early AFX	942	818	731	630	554	308	167	65	26
Endurant	6606	4872	3525	2483	1653	1049	591	298	142
Zenith	3281	2549	2006	1569	1145	750	437	239	127
Late AFX	1350	977	617	282	<11				
Excluder	8310	5779	4037	2834	1833	1144	652	359	204

Images courtesy of British Medical Journal Publishing Group. Used with permission.

Across all endografts, mortality was similar within the first decade after EVAR.

The long-term follow-up:
VQI-VISION* dataset

20,489
EVAR patients

282
U.S. centers

> 40%
with the EXCLUDER® Device

For more information on this unique surveillance study, access the full published results and appendix today.

Full publication

Appendix

* VQI-VISION, Vascular Quality Initiative - Vascular Implant Surveillance and Interventional Outcomes Network.

See reverse side for references and product indications.

Together, improving life

References

1. Hoel AW, Faerber AE, Moore KO, *et al*. A pilot study for long-term outcome assessment after aortic aneurysm repair using Vascular Quality Initiative data matched to Medicare claims. *Journal of Vascular Surgery* 2017;66(3):751-759.e1
2. Centers for Medicare & Medicaid Services (CMS). Accessed March 17, 2017. https://www.cms.gov/
3. Goodney P, Mao J, Jesse Columbo J, *et al*; on behalf of the Society for Vascular Surgery's Patient Safety Organization. Use of linked registry claims data for long term surveillance of devices after endovascular abdominal aortic aneurysm repair: observational surveillance study. *BMJ* 2022;379:e071452

Consult Instructions for Use
eifu.goremedical.com

INDICATIONS FOR USE IN THE U.S.: The GORE® EXCLUDER® AAA Endoprosthesis is intended to exclude the aneurysm from the blood circulation in patients diagnosed with infrarenal abdominal aortic aneurysm (AAA) disease and who have appropriate anatomy as described below: Adequate iliac/femoral access; Infrarenal aortic neck treatment diameter range of 19–32 mm and a minimum aortic neck length of 15 mm; Proximal aortic neck angulation ≤ 60°; Iliac artery treatment diameter range of 8–25 mm and iliac distal vessel seal zone length of at least 10 mm. **Aortic Extender and Iliac Extender Endoprosthesis.** The Aortic and Iliac Extender Endoprostheses are intended to be used after deployment of the GORE® EXCLUDER® AAA Endoprosthesis. These extensions are intended to be used when additional length and/or sealing for aneurysmal exclusion is desired. **CONTRAINDICATIONS:** The GORE® EXCLUDER® AAA Endoprosthesis is contraindicated in: patients with known sensitivities or allergies to the device materials; patients with a systemic infection who may be at increased risk of endovascular graft infection. Refer to *Instructions for Use* at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. ℞ Only

Products listed may not be available in all markets.

W. L. Gore & Associates, Inc.
goremedical.com

Asia Pacific +65 67332882 **Australia/New Zealand** 1800 680 424 **Europe** 00800 6334 4673
United States Flagstaff, AZ 86004 800 437 8181 928 779 2771